Nanotech Investing Universal Ibogaine Provides Bi-weekly Default Status Report on 2025 Year-end Filings and Update on Restructuring Process
Nanotech Investing Universal Ibogaine advises further on application for Management Cease Trade Order
life science investing Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference
life science investing Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors
life science investing Universal Ibogaine to Participate in the 2022 Virtual Growth Conference - Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
life science investing UNIVERSAL IBOGAINE EXPANDS RESEARCH TEAM WITH JULIE DUMOUCHEL, DIRECTOR OF CLINICAL TRIALS
